Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:IMRX NASDAQ:LIMN NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.48+0.7%$1.61$1.13▼$2.66$132.08M2.61402,825 shs179,878 shsIMRXImmuneering$3.22-0.9%$3.31$1.00▼$4.69$115.89M0.371.24 million shs201,528 shsLIMNLiminatus Pharma$4.40+1.1%$0.00$4.10▼$33.66$114.44MN/A529,124 shs316,634 shsSNYRSynergy CHC$3.86-1.5%$3.09$1.19▼$10.00$35.49MN/A478,553 shs29,862 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-2.00%+0.68%-7.55%+12.21%-11.98%IMRXImmuneering+1.25%-8.96%-26.47%+157.94%+185.09%LIMNLiminatus Pharma-2.90%-11.94%-34.59%+434,999,900.00%+434,999,900.00%SNYRSynergy CHC+2.08%+9.50%+26.05%+102.06%+12,966.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.9363 of 5 stars3.54.00.00.01.80.00.0IMRXImmuneering3.5616 of 5 stars3.33.00.00.02.95.00.6LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/ASNYRSynergy CHC3.9615 of 5 stars3.80.00.00.03.33.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00170.27% UpsideIMRXImmuneering 2.60Moderate Buy$13.25311.49% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/ASNYRSynergy CHC 3.50Strong Buy$10.00159.07% UpsideCurrent Analyst Ratings BreakdownLatest SNYR, CGEN, LIMN, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.86M4.74N/AN/A$0.56 per share2.64IMRXImmuneering$320K362.15N/AN/A$1.33 per share2.42LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/ASNYRSynergy CHC$33.59M1.06$0.27 per share14.43($1.91) per share-2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%N/AIMRXImmuneering-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/19/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/ASNYRSynergy CHC$2.12MN/A0.006.54N/AN/A-8.48%12.75%N/ALatest SNYR, CGEN, LIMN, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 million5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/15/2025Q1 2025SNYRSynergy CHC$0.07$0.10+$0.03$0.10$9.03 million$8.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A4.744.74IMRXImmuneeringN/A7.487.48LIMNLiminatus PharmaN/AN/AN/ASNYRSynergy CHCN/A1.911.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%IMRXImmuneering67.65%LIMNLiminatus PharmaN/ASNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipCGENCompugen9.50%IMRXImmuneering22.90%LIMNLiminatus PharmaN/ASNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableIMRXImmuneering6035.99 million27.75 millionNot OptionableLIMNLiminatus PharmaN/A26.01 millionN/AN/ASNYRSynergy CHC409.19 million3.99 millionN/ASNYR, CGEN, LIMN, and IMRX HeadlinesRecent News About These CompaniesHead-To-Head Contrast: Synergy CHC (NASDAQ:SNYR) vs. Krispy Kreme (NASDAQ:DNUT)August 10 at 3:59 AM | americanbankingnews.comNew to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion RateAugust 5, 2025 | indystar.comINew to The Street Launches 1,000+ Commercial TV Blitz for Synergy CHC ($SNYR), Makers of Focus Factor(R) – Adds NewsOut Video PR Coverage & NYC #1 Market SaturationAugust 5, 2025 | desmoinesregister.comDJack Ross Buys Handful Of Shares In Synergy CHCAugust 3, 2025 | finance.yahoo.comInsider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of StockAugust 1, 2025 | insidertrades.comSynergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call InformationJuly 31, 2025 | manilatimes.netMSynergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution ExpansionJuly 31, 2025 | quiverquant.comQSynergy CHC Expands Retail Presence in North AmericaJune 30, 2025 | tipranks.comSynergy CHC Corp. (SNYR) Stock Price Today - WSJJune 24, 2025 | wsj.comSynergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue StreamsJune 18, 2025 | finance.yahoo.comSynergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in RevenueJune 18, 2025 | quiverquant.comQHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 18, 2025 | finance.yahoo.comHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 16, 2025 | insidermonkey.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 SharesJune 12, 2025 | insidertrades.comNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global ExpansionJune 11, 2025 | freep.comFNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global ExpansionJune 10, 2025 | guardonline.comGSynergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage ExpansionJune 10, 2025 | quiverquant.comQSynergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global ExpansionJune 10, 2025 | globenewswire.comSynergy CHC secures $20 million loan for growth and debt repaymentJune 5, 2025 | investing.comSynergy CHC Secures $20 Million Loan AgreementJune 4, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNYR, CGEN, LIMN, and IMRX Company DescriptionsCompugen NASDAQ:CGEN$1.48 +0.01 (+0.68%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.01 (+0.34%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Immuneering NASDAQ:IMRX$3.22 -0.03 (-0.92%) Closing price 04:00 PM EasternExtended Trading$3.29 +0.07 (+2.17%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Liminatus Pharma NASDAQ:LIMN$4.40 +0.05 (+1.15%) As of 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Synergy CHC NASDAQ:SNYR$3.86 -0.06 (-1.53%) As of 03:59 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access